NCT04733833已完成2 期
A Randomized, Controlled Study to Evaluate the Efficacy and Safety of VB-201 in Patients With COVID-19
Vascular Biogenics Ltd. operating as VBL Therapeutics1 个研究点 分布在 1 个国家目标入组 5 人开始时间: 2021年1月26日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 5
- 试验地点
- 1
- 主要终点
- Assess the safety and tolerability of VB-201
研究概览
简要总结
The purpose of this Phase 2 study is to test safety, efficacy, and tolerability of an oral preparation of VB-201 in patients with severe COVID-19
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Signed and approved informed consent before initiation of protocol-specified procedures;
- •Male or female subjects, ≥18 to ≤80 years of age with COVID-19
- •SARS-2-CoV-2 infection confirmed by PCR in the last 8 days
- •Hospitalized
- •Symptoms of Severe COVID-19 as demonstrated by one of the following:
- •Respiratory frequency >30 breaths per minute
- •SpO2 <94% on room air at sea level
- •Ratio of arterial partial pressure of oxygen to fraction of inspired oxygen (PaO2/FiO2) <300 mmHg
- •lung infiltrates >50%
- •For a female subject; either:
- •subject is of non-childbearing potential, defined as: menopause with amenorrhea >1 years, hysterectomy, or bilateral oopherectomy or
- •agrees to continue to use highly effective methods of birth control defined as those alone or in combination that result in a low failure rate (<1%) when used consistently and correctly throughout the study and for at least one month following treatment termination and have a negative pregnancy test at screening and before the first dose of study drug; Males must use at least one method of contraception (e.g. condom) throughout the study and for 90 days following the last dose of study drug;
- •In the opinion of the investigator, the subject will be compliant and have a high probability of completing the study and all required procedures.
排除标准
- •Evidence of critical COVID-19 based on any of the following
- •Admission to ICU
- •Assisted ventilation (invasive or non-invasive)
- •ECMO or hemofiltration required
- •Acute Cardiac Failure
- •Bacterial co-infection
- •Co-infection with other common viral pneumonias (e.g. Influenza)
- •Participation in another interventional clinical trial or intention to participate in another interventional study during the course of this study;
- •In the opinion of the investigator, unlikely to survive for at least 48 hours from screening or anticipate mechanical ventilation within 48 hours
- •Unable to take oral medication
- •History of gastrointestinal illness that may cause nausea and vomiting
- •Subjects with any laboratory test at screening that common medical practice would deem as significantly abnormal. For example:
- •Alanine transaminase (ALT), aspartate transaminase (AST), or alkaline phosphatase >5.0 times the upper limit of normal (ULN) or
- •Creatinine clearance <30 mL/min
- •The subject has a known allergy or sensitivity to the study treatment or to any of the excipients contained in the study drug formulation (see list of ingredients in the Investigator's Brochure);
- •Female subject with a positive pregnancy test or nursing, or planning a pregnancy during the course of the study;
- •Unwilling or unable to comply with study requirements
研究组 & 干预措施
Arm 1
Experimental
VB-201 + standard of care
干预措施: VB-201 + Standard of care (Drug)
Arm 2
Active Comparator
Standard of care
干预措施: Standard of care (Drug)
结局指标
主要结局
Assess the safety and tolerability of VB-201
时间窗: Subjects will participate in the study for approximately 7 weeks: up to 1 day for screening and establishment of baseline, followed by 14 days of treatment and a follow-up visit 4 weeks after last dose of study medication.
Number of participants with treatment-related adverse events as assessed by CTCAE v5.0 (Time frame: Adverse events will be collected from the time the informed consent is signed through 28 days after the subject's last dose. All adverse events that are ongoing at the time of completion/discontinuation will be followed until resolution or the event is chronic or stable in the opinion of the investigator).
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
2 期
Safety and Efficacy of APG-157 in Head and Neck CancerHead and Neck CancerSquamous Cell Carcinoma of Oral CavitySquamous Cell Carcinoma of the OropharynxNCT05312710Aveta Biomics, Inc.24
已完成
2 期
Phase II Hedgehog Inhibitor for Myelodysplastic Syndrome (MDS)Myelodysplastic Syndrome (MDS)Chronic Myelomonocytic Leukemia (CMML)NCT01842646H. Lee Moffitt Cancer Center and Research Institute35
已完成
2 期
Safety, Tolerability, and Treatment Effect of Belnacasan in Patients With COVID-19COVID-19NCT05164120MedStar Health43
已完成
2 期
A Phase 2 Study to Evaluate Efficacy and Safety of VX-561 in Subjects Aged 18 Years and Older With Cystic FibrosisCystic FibrosisNCT03911713Vertex Pharmaceuticals Incorporated77
进行中（未招募）
2 期
A Phase 2 Study to Evaluate DNTH103 in Adults With Generalized Myasthenia Gravis (MAGIC)Myasthenia Gravis, GeneralizedNCT06282159Dianthus Therapeutics65